The Department of Biotechnology (DBT), Ministry of Science & Technology has announced that it has approved additional funding towards clinical studies of India's 'first of its kind' mRNA-based COVID-19 vaccine – HGCO19, developed by Pune-based biotechnology company Gennova Biopharmaceuticals.

This funding has been awarded under the 'Mission COVID Suraksha- The Indian COVID-19 Vaccine Development Mission' by DBT's dedicated Mission Implementation Unit at Biotechnology Industry Research Assistance Council (BIRAC) after multiple rounds of evaluation of all the applications that were submitted in response to the 'Request for Expression of Interest (REOI)' under Mission COVID Suraksha for the'Development of COVID-19 vaccine candidate(s)'.

Leave a Reply

Your email address will not be published. Required fields are marked *